Philip W. Stashak

Learn More
The dose-response relationships in mice immunized with capsular polysaccharide of type 3 Streptococcus pneumoniae (SSS-III) show a distinctive pattern characterized by a single optimal dose for immunization within a relatively narrow range of immunizing doses. Most of the antibody produced is of the IgM class, and the kinetics for the development of both(More)
Prior treatment (priming) with a subimmunogenic dose of type III pneumococcal polysaccharide results in the development of an antigen-specific state of unresponsiveness termed low-dose paralysis. Such unresponsiveness can be transferred by spleen cells obtained from mice within 5 to 24 hr after priming; the suppressive activity of transferred cells is(More)
Studies conducted with F1 and F2 progeny of crosses between strains of inbred mice that differ greatly in their capacity to make an antibody response to type III pneumococcal polysaccharide, dextran B-1355, and lipopolysaccharide from Escherichia coli 0113 have shown that multiple genes influence the magnitude of the antibody response to these antigens.(More)
The IgM antibody response to Type III pneumococcal polysaccharide (SSS-III) was assessed in F(1), F(2), and backcross progeny derived from high (BALB/cAnN) and extremely low (CBA/HN) responding parental strains of inbred mice. The results of these studies indicated that a major component involved in the antibody response is X-linked, i.e., carried on the X(More)
Amplifier T cell activity can be transferred by spleen cells harvested 72 hr after priming with type III pneumococcal polysaccharide (SSS-III) and can be abolished by treating the transferred cells with monoclonal anti-Lyt-1, or anti-Thy-1 antibodies in the presence of complement; thus, amplifier cells represent a distinct subpopulation of T cells.(More)